Cephalon Australia Pty Ltd.
Records under this name other than patents Cephalon Australia Pty Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Cephalon Australia Pty Ltd.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,505,826 | Modified antibody with improved half-life Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,963,515 | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,563,697 | Anti-IL-12/IL-23 antibodies Formerly held Lapsed on the fee record Ended Oct 22, 2021 · USPTO record | Lapsed on the fee record | Ended Oct 22, 2021 | USPTO record |
| US 8,343,490 | Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent Formerly held Lapsed on the fee record Ended Jan 1, 2021 · USPTO record | Lapsed on the fee record | Ended Jan 1, 2021 | USPTO record |
| US 8,273,349 | Binding member which binds to both lewis-Y and lewis-B haptens, and its use for treating cancer Formerly held Lapsed on the fee record Ended Sep 25, 2020 · USPTO record | Lapsed on the fee record | Ended Sep 25, 2020 | USPTO record |
| US 7,267,821 | Binding member which binds to both Lewisy and Lewisb haptens, and its use for treating cancer Formerly held Lapsed on the fee record Ended Sep 11, 2019 · USPTO record | Lapsed on the fee record | Ended Sep 11, 2019 | USPTO record |
| US 9,127,057 | Anti-IL-23 heterodimer specific antibodies Formerly held Lapsed on the fee record Ended Sep 8, 2019 · USPTO record | Lapsed on the fee record | Ended Sep 8, 2019 | USPTO record |
| US 7,915,387 | Monoclonal antibody Sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent Formerly held Lapsed on the fee record Ended Mar 29, 2019 · USPTO record | Lapsed on the fee record | Ended Mar 29, 2019 | USPTO record |
| US 7,879,983 | Binding member which binds to both Lewis-y and Lewis-b haptens, and its use for treating cancer Formerly held Lapsed on the fee record Ended Feb 1, 2019 · USPTO record | Lapsed on the fee record | Ended Feb 1, 2019 | USPTO record |
| US 8,932,588 | Treatment of cancer involving mutated KRAS or BRAF genes Formerly held Lapsed on the fee record Ended Jan 13, 2019 · USPTO record | Lapsed on the fee record | Ended Jan 13, 2019 | USPTO record |